Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24241722,molar extinction coefficients,All the tested PTZs exhibited potent UVA/B absorption with molar extinction coefficients of ca. 3400-4400 M(-1)cm(-1).,Photosafety screening of phenothiazine derivatives with combined use of photochemical and cassette-dosing pharmacokinetic data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24241722/),1/[M],3400-4400,47219,DB00623,Fluphenazine
,8911886,Cmax,"The concentration maxima after administration of the slow release formulation were approximately half those measured after the immediate release formulation and were recorded later by a factor of 2 (immediate release: Cmax = 2.3 ng.ml-1, tmax = 2.8 h; slow release: Cmax = 1.2 ng.ml-1, tmax = 4.6 h).",Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911886/),[ng] / [ml],2.3,50297,DB00623,Fluphenazine
,8911886,tmax,"The concentration maxima after administration of the slow release formulation were approximately half those measured after the immediate release formulation and were recorded later by a factor of 2 (immediate release: Cmax = 2.3 ng.ml-1, tmax = 2.8 h; slow release: Cmax = 1.2 ng.ml-1, tmax = 4.6 h).",Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911886/),h,2.8,50298,DB00623,Fluphenazine
,8911886,Cmax,"The concentration maxima after administration of the slow release formulation were approximately half those measured after the immediate release formulation and were recorded later by a factor of 2 (immediate release: Cmax = 2.3 ng.ml-1, tmax = 2.8 h; slow release: Cmax = 1.2 ng.ml-1, tmax = 4.6 h).",Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911886/),[ng] / [ml],1.2,50299,DB00623,Fluphenazine
,8911886,tmax,"The concentration maxima after administration of the slow release formulation were approximately half those measured after the immediate release formulation and were recorded later by a factor of 2 (immediate release: Cmax = 2.3 ng.ml-1, tmax = 2.8 h; slow release: Cmax = 1.2 ng.ml-1, tmax = 4.6 h).",Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911886/),h,4.6,50300,DB00623,Fluphenazine
,8911886,absolute bioavailability,The geometric means for the absolute bioavailability of fluphenazine were 2.7% for the immediate release formulation and 3.4% for the slow release formulation.,Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911886/),%,2.7,50301,DB00623,Fluphenazine
,8911886,absolute bioavailability,The geometric means for the absolute bioavailability of fluphenazine were 2.7% for the immediate release formulation and 3.4% for the slow release formulation.,Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911886/),%,3.4,50302,DB00623,Fluphenazine
,9755905,half-life,"Following administration of fluphenazine decanoate, the amount of prodrug at the sites of injection declined exponentially (half-life 3.4 days).",The roles of depot injection sites and proximal lymph nodes in the presystemic absorption of fluphenazine decanoate and fluphenazine: ex vivo experiments in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755905/),d,3.4,51349,DB00623,Fluphenazine
,9755905,half-life,The half-life for the decline of fluphenazine from lymph nodes (4.6 days) was similar to that from plasma (4.3 days).,The roles of depot injection sites and proximal lymph nodes in the presystemic absorption of fluphenazine decanoate and fluphenazine: ex vivo experiments in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755905/),d,4.6,51350,DB00623,Fluphenazine
,9755905,half-life,The half-life for the decline of fluphenazine from lymph nodes (4.6 days) was similar to that from plasma (4.3 days).,The roles of depot injection sites and proximal lymph nodes in the presystemic absorption of fluphenazine decanoate and fluphenazine: ex vivo experiments in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755905/),d,4.3,51351,DB00623,Fluphenazine
,9279892,Clearance (CL),"After intravenous FLU-D, the pharmacokinetics of the prodrug (mean +/- SD) were as follows: Clearance (CL) 42.9 +/- 6.3 L/h; terminal half-life (t1/2) 3.5 +/- 0.8 h; volume of distribution (Vd) 216 +/- 61 L.",Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279892/),[l] / [h],42.9,58345,DB00623,Fluphenazine
,9279892,terminal half-life (t1/2),"After intravenous FLU-D, the pharmacokinetics of the prodrug (mean +/- SD) were as follows: Clearance (CL) 42.9 +/- 6.3 L/h; terminal half-life (t1/2) 3.5 +/- 0.8 h; volume of distribution (Vd) 216 +/- 61 L.",Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279892/),h,3.5,58346,DB00623,Fluphenazine
,9279892,volume of distribution (Vd),"After intravenous FLU-D, the pharmacokinetics of the prodrug (mean +/- SD) were as follows: Clearance (CL) 42.9 +/- 6.3 L/h; terminal half-life (t1/2) 3.5 +/- 0.8 h; volume of distribution (Vd) 216 +/- 61 L.",Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279892/),l,216,58347,DB00623,Fluphenazine
,9279892,fractional availability,The fractional availability of FLU was 1.0 +/- 0.2.,Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279892/),,1.0,58348,DB00623,Fluphenazine
,9279892,volume of distribution,"After intravenous FLU, the volume of distribution of FLU (51 +/- 17.8 L) was some 4 fold less than that of the prodrug.",Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279892/),l,51,58349,DB00623,Fluphenazine
,9279892,apparent t1/2,"After intramuscular FLU-D in sesame oil, the apparent t1/2 of FLU was 9.7 +/- 2.0 days whereas after intramuscular FLU base in sesame oil, the apparent t1/2 was only 7.7 +/- 3.4 h showing that the absorption of FLU itself from the intramuscular site and proximal lymph nodes is relatively rapid.",Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279892/),d,9.7,58350,DB00623,Fluphenazine
,9279892,apparent t1/2,"After intramuscular FLU-D in sesame oil, the apparent t1/2 of FLU was 9.7 +/- 2.0 days whereas after intramuscular FLU base in sesame oil, the apparent t1/2 was only 7.7 +/- 3.4 h showing that the absorption of FLU itself from the intramuscular site and proximal lymph nodes is relatively rapid.",Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279892/),h,7.7,58351,DB00623,Fluphenazine
,7658345,peak concentration (Cmax),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[ng] / [ml],7.15,67443,DB00623,Fluphenazine
,7658345,time to Cmax (Tmax),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),h,1.32,67444,DB00623,Fluphenazine
,7658345,time to Cmax (Tmax),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[1] / [h],2.07,67445,DB00623,Fluphenazine
,7658345,rate of absorption (Ka),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),h,1.32,67446,DB00623,Fluphenazine
,7658345,rate of absorption (Ka),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[1] / [h],2.07,67447,DB00623,Fluphenazine
,7658345,area under the curve from 0 to 72 h (AUC0-72),"The results of the latter single dose studies demonstrated that the mean +/- SD for the peak concentration (Cmax), the time to Cmax (Tmax), the rate of absorption (Ka), and the area under the curve from 0 to 72 h (AUC0-72) were found to be 7.15 +/- 2.58 ng/mL, 1.32 +/- 0.58 h, 2.07 +/- 0.93 1/h, and 201 +/- 71 ng h/mL, respectively.",Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7658345/),[hÂ·ng] / [ml],201,67448,DB00623,Fluphenazine
,2864156,apparent elimination half-life,The enanthate produces peak plasma concentrations on days 2 to 3 and declines with an apparent elimination half-life (i.e. the half-time of the apparent first-order decline of plasma concentrations) of 3.5 to 4 days after a single injection.,Clinical pharmacokinetics of the depot antipsychotics. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,3.5 to 4,72901,DB00623,Fluphenazine
,2864156,half-time of the apparent first-order decline of plasma concentrations,The enanthate produces peak plasma concentrations on days 2 to 3 and declines with an apparent elimination half-life (i.e. the half-time of the apparent first-order decline of plasma concentrations) of 3.5 to 4 days after a single injection.,Clinical pharmacokinetics of the depot antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,3.5 to 4,72902,DB00623,Fluphenazine
,2864156,apparent half-life,The decanoate produces an early high peak which occurs during the first day and then declines with an apparent half-life ranging from 6.8 to 9.6 days following a single injection.,Clinical pharmacokinetics of the depot antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,6.8 to 9.6,72903,DB00623,Fluphenazine
,2864156,apparent half-life,"After multiple injections of fluphenazine decanoate, however, the mean apparent half-life increases to 14.3 days, and the time to reach steady-state is 4 to 6 weeks.",Clinical pharmacokinetics of the depot antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,14.3,72904,DB00623,Fluphenazine
,2864156,time to reach steady-state,"After multiple injections of fluphenazine decanoate, however, the mean apparent half-life increases to 14.3 days, and the time to reach steady-state is 4 to 6 weeks.",Clinical pharmacokinetics of the depot antipsychotics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),weeks,4 to 6,72905,DB00623,Fluphenazine
,2349370,absorption half-life,"Results suggested an absorption half-life of 4 weeks, although, in three cases steady state was only achieved after 11 monthly injections.",Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. ,"t1/2,Î±-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2349370/),weeks,4,129015,DB00623,Fluphenazine
,2885172,T 1/2,"Mean value of T 1/2 of clopenthixol decanoate and haloperidol decanoate are 19 and 21 days, respectively, they thereby justify monthly administration.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,19,227924,DB00623,Fluphenazine
,2885172,T 1/2,"Mean value of T 1/2 of clopenthixol decanoate and haloperidol decanoate are 19 and 21 days, respectively, they thereby justify monthly administration.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,21,227925,DB00623,Fluphenazine
,2885172,half-lives,"Flupenthixol decanoate and fluphenazine enanthate should be injected with dosing intervals of 3 and 1 weeks, respectively in respect with their half-lives: 17 and 4 days.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,17,227926,DB00623,Fluphenazine
,2885172,half-lives,"Flupenthixol decanoate and fluphenazine enanthate should be injected with dosing intervals of 3 and 1 weeks, respectively in respect with their half-lives: 17 and 4 days.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,4,227927,DB00623,Fluphenazine
,2885172,half-life,"Fluphenazine decanoate have a half-life of 14 days, however, the longer time the treatment, the longer the apparent half-life, suggesting to reduce the dose or to enlarge the dosing interval.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,14,227928,DB00623,Fluphenazine
,6787637,terminal half-life,The mean terminal half-life of fluphenazine (+ or - SD) was 16.4 + or - 13.3 h.,Fluphenazine pharmacokinetics and therapeutic response. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6787637/),h,16.4,247340,DB00623,Fluphenazine
